Early Phase Technology Selection: Strategies To Overcome Development Challenges

Summary:
According to recent reports from the Tufts Center for the Study of Drug Development (CSDD), only about 12% of drugs that begin clinical testing eventually gain regulatory approval, and those few successes require an average of 15 years of development. At a roundtable hosted by the Center in 2015, CSDD’s Director of Sponsored Research, Ken Getz, observed, “The pay-off for companies that can reduce clinical time and cost is potentially large, as our research has found, for example, that a 10% improvement in cycle time and success rates can shave $634 million off the total capitalized cost of $2.6 billion required, on average, to bring a new drug to market.”